One of the longest-running companies involved in diabetes technology is Medtronic Diabetes, which has had a twisting pathway in its product pipeline over the years. The company has been the leader in insulin pumps dating back decades and was the first to launch a combo device with a continuous glucose monitor (CGM).
As a powerful Pharma industry leader, patients tend to have a love-hate relationship with this company — appreciating their offerings but not always their customer service or marketing tactics. No matter how you slice it, Medtronic Diabetes does help lead the way in diabetes technology, so it’s important to know what the company is up to.
Here’s a deep dive into what Medtronic Diabetes is offering in 2020 and beyond:
What is Medtronic?
What Is Medtronic Known For? – Medtronic is a global producer of medical devices and therapies, such as insulin pumps, pacemakers, and diabetes therapies. Perhaps best known for its revolutionary cardiac devices, such as battery-powered and miniature pacemakers, it also has introduced cutting-edge products into the industry.
What is the new device for diabetes?
News Release Wednesday, September 28, 2022 Next-generation technology maintains blood glucose levels by automatically delivering insulin. 
iLet bionic pancreas device Beta Bionics A device known as a bionic pancreas, which uses next-generation technology to automatically deliver insulin, was more effective at maintaining blood glucose (sugar) levels within normal range than standard-of-care management among people with type 1 diabetes, a new multicenter clinical trial has found.
- The trial was primarily funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, and published in the New England Journal of Medicine,
- Automated insulin delivery systems, also called artificial pancreas or closed-loop control systems, track a person’s blood glucose levels using a continuous glucose monitor and automatically deliver the hormone insulin when needed using an insulin pump.
These systems replace reliance on testing glucose level by fingerstick, continuous glucose monitor with separate insulin delivery through multiple daily injections, or a pump without automation. Compared to other available artificial pancreas technologies, the bionic pancreas requires less user input and provides more automation because the device’s algorithms continually adjust insulin doses automatically based on users’ needs.
- Users initialize the bionic pancreas by entering their body weight into the device’s dosing software at the time of first use.
- Users of the bionic pancreas also do not have to count carbohydrates, nor initiate doses of insulin to correct for high blood glucose.
- In addition, health care providers do not need to make periodic adjustments to the settings of the device.
“Keeping tight control over blood glucose is important in managing diabetes and is the best way to prevent complications like eye, nerve, kidney, and cardiovascular disease down the road,” said Dr. Guillermo Arreaza-Rubín, director of NIDDK’s diabetes technology program.
The bionic pancreas technology introduces a new level of ease to the day-to-day management of type 1 diabetes, which may contribute to improved quality of life.” The 13-week trial, conducted at 16 clinical sites across the United States, enrolled 326 participants ages 6 to 79 years who had type 1 diabetes and had been using insulin for at least one year.
Participants were randomly assigned to either a treatment group using the bionic pancreas device or a standard-of-care control group using their personal pre-study insulin delivery method. All participants in the control group were provided with a continuous glucose monitor, and nearly one-third of the control group were using commercially available artificial pancreas technology during the study.
In participants using the bionic pancreas, glycated hemoglobin, a measure of a person’s long-term blood glucose control, improved from 7.9% to 7.3%, yet remained unchanged among the standard-of-care control group. The bionic pancreas group participants spent 11% more time, approximately 2.5 hours per day, within the targeted blood glucose range compared to the control group.
These results were similar in youth and adult participants, and improvements in blood glucose control were greatest among participants who had higher blood glucose levels at the beginning of the study. “Our observation that this system can safely improve glucose control to the degree we found, and do so despite requiring much less input from users and their health care providers, has important implications for children and adults living with diabetes,” said Dr.
- Steven Russell, study chair, associate professor of medicine at Harvard Medical School, and staff physician at the Massachusetts General Hospital in Boston.
- Hyperglycemia, or high blood glucose, caused by problems with insulin pump equipment, was the most frequently reported adverse event in the bionic pancreas group.
The number of mild hypoglycemia events, or low blood glucose, was low and was not different between the groups. The frequency of severe hypoglycemia was not statistically different between the standard of care and bionic pancreas groups. Four companion papers were also published in Diabetes Technology and Therapeutics, two of which provided more detailed results among the adult and youth participants.
- The third paper reported results from an extension study in which the participants from the standard-of-care control group switched to using the bionic pancreas for 13 weeks and experienced improvements in glucose control similar to the bionic pancreas group in the randomized trial.
- In the fourth paper, results showed that using the bionic pancreas with a faster-acting insulin in 114 adult participants improved glucose control as effectively as using the device with standard insulin.
“NIDDK’s decades-long investment in developing advanced technologies for diabetes management has reached another promising milestone and continues to provide significant return,” said NIDDK Director Dr. Griffin P. Rodgers. “While we continue to search for a cure for type 1 diabetes, devices like the bionic pancreas can allow people to worry less about their blood-glucose levels and focus more on living their fullest, healthiest lives.” Dr.
- Edward Damiano, project principal investigator, professor of biomedical engineering at Boston University, and founder and executive chair of Beta Bionics, Inc., concurs.
- The completion of this study represents a major milestone for the bionic pancreas initiative, which simply would not have been possible had it not been for the support provided by the NIDDK over the years.” The study is one of several pivotal trials funded by NIDDK to advance artificial pancreas technology and look at factors including safety, efficacy, user-friendliness, physical and emotional health of participants, and cost.
To date, these trials have provided the important safety and efficacy data needed for regulatory review and licensure to make the technology commercially available. The Jaeb Center for Health Research in Tampa, Florida, served as coordinating center. Funding for the study was provided by NIDDK grant 1UC4DK108612 to Boston University, by an Investigator-Initiated Study award from Novo Nordisk, and by Beta Bionics, Inc., which also provided the experimental bionic pancreas devices used in the study.
- Insulin and some supplies were donated by Novo Nordisk, Eli Lilly, Dexcom, and Ascensia Diabetes Care.
- Partial support for the development of the experimental bionic pancreas device was provided by NIDDK Small Business Innovation Research (SBIR) grant 1R44DK120234 to Beta Bionics, Inc.
- The NIDDK, a component of the NIH, conducts and supports research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic, and hematologic diseases.
Spanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe and disabling conditions affecting Americans. For more information about the NIDDK and its programs, see https://www.niddk.nih.gov/,
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases.
For more information about NIH and its programs, visit www.nih.gov, NIHTurning Discovery Into Health ® ###
What is Medtronic artificial pancreas?
DreaMed Diabetes ‘ artificial pancreas algorithm is being used in Medtronic ‘s new CE marked MiniMed 780G Advanced Hybrid Closed Loop system. The development of the MD-Logic algorithm was initiated at the Institute of Endocrinology and Diabetes at the Schneider Children’s Medical Centre of Israel headed by Prof.
- Moshe Phillip in 2007.
- The project spawned the creation of DreaMed Diabetes and an agreement with Medtronic, leading to the implementation of the algorithm into the MiniMed 780G system.
- The ” MD-Logic Artificial Pancreas algorithm,” is an advanced hybrid closed loop system for controlling patient glucose levels.
It can alter both basal insulin and provide automatic correction boluses in real time, while changing the way these correction boluses are provided. This process depends on sensor glucose reading dynamics and the information from the insulin pump. The MD-Logic technology’s effectiveness was validated in many clinical studies.
- The technology was the first to be tested in a multicentre, multinational randomised controlled study in a diabetes camp, as chronicled by a study in the New England Journal of Medicine.
- In June 2012, the technology was also the first to be used by patients at home, and in 2015 it was the first to receive regulatory approval from EU authorities.
Now, Medtronic is using MD-Logic artificial pancreas algorithm in the automatic correction boluses of its next generation MiniMed 780G system, a system that will be used by many people with type 1 diabetes around the world. Adding this capability to the MiniMed 780G system will fulfil many unmet needs of people with diabetes, such as with controlling glucose around meals.
Specifically, it will help mitigate the hyperglycaemia that results from missed or late meal boluses, as well as the hyper- and hypoglycaemia that often result from inaccurate calculation of the carbohydrate content of a meal. DreaMed Diabetes CEO and co-founder Eran Atlas said: “I would like to congratulate the Diabetes Group at Medtronic and DreaMed founders for achieving this important milestone.
We are proud to be a part of the latest update in the Medtronic MiniMed line of products, optimizing the insulin delivery of each user. DreaMed’s partnership with the Medtronic team served as our first step toward fulfilling our dream of bringing and developing different types of solutions dedicated to improving the care and glucose control of people with diabetes.
- Our current focus is on our DreaMed Advisor platform which is already being adopted by leading diabetes centres in the U.S.
- We are thrilled that our first professional life mission is live and will have a positive impact on many people around the world.” Dr.
- Robert Vigersky, chief medical officer, global medical and clinical affairs for diabetes group at Medtronic, added: “Collaboration is key to driving innovations that make a meaningful difference in the lives of people living with diabetes.
Our ongoing work with DreaMed Diabetes over the years has now resulted in a next generation advanced hybrid closed loop that we believe will further simplify diabetes management.”
What is insulin sensitivity factor Medtronic?
Changing Your Bolus Wizard Settings – Did You Know: The Bolus Wizard is a feature that calculates an estimated bolus in order to cover any carbohydrates (carbs) you eat or drink or to correct a high blood glucose. Important: Work with your healthcare team to establish your personal settings, which includes your carb ratio, insulin sensitivity, blood glucose (BG) target, and active insulin time.
- Once these settings are entered, you only need your current BG and carb value (for a meal bolus) for the Bolus Wizard feature to calculate your bolus amount.
- Note: If you do not enter all the required settings, the MISSING INFO screen appears, listing any missing information.
- You must program all settings before you can use the Bolus Wizard feature.
After you enter all your settings, review them for accuracy. Turning on the Bolus Wizard Feature Device: MiniMed ® 530G (551/751), Revel (523/723), 522/722, 515/715, 512/712 Go to the EDIT SETTINGS screen.
- For MiniMed 530G (551/751), Revel (523/723) Main Menu > Bolus > Bolus Setup > Bolus Wizard Setup > Edit Settings
- For 522/722, 515/715, 512/712 Main Menu > Bolus > Bolus Wizard Setup > Edit Settings
- The EDIT SETTINGS screen appears with Wizard: OFF selected. Press ACT,
- The WIZARD ON/OFF screen appears. Select ON, then press ACT,
- The EDIT SETTINGS screen appears, showing that the wizard is now turned on.
Note: If you do not enter all the required settings, the MISSING INFO screen appears, listing any missing information. You must program all settings before you can use the Bolus Wizard feature. After you enter all your settings, review them for accuracy.
Selecting the Carb Units Device: MiniMed 530G (551/751), Revel (523/723), 522/722, 515/715, 512/712 Did You Know: The Carb Unit setting tells your insulin pump whether to count your carbohydrate units as grams or exchanges. Your insulin pump uses this information when it calculates a bolus. Make sure the EDIT SETTINGS screen is open.
- For MiniMed 530G (551/751), Revel (523/723) Main Menu > Bolus > Bolus Setup > Bolus Wizard Setup > Edit Settings
- For 522/722, 515/715, 512/712 Main Menu > Bolus > Bolus Wizard Setup > Edit Settings
- Select Carb Units, then press ACT,
- The CARB UNITS screen appears. Select Grams or Exchanges, then press ACT,
- The EDIT SETTINGS screen shows the carb units you selected.
Setting the Carb/Exch Ratios Device: MiniMed 530G (551/751), Revel (523/723), 522/722, 515/715, 512/712 Did You Know: Because your carb ratios (or exchange ratios) may vary throughout the day, you can set up to 8 different ratios by using the Carb/Exch Ratio setting. If your first carb/exchange ratio spans less than 24 hours, a second carb/exch ratio screen appears.
| Device | Allowed Range | Default Setting | Increments (Grams/Unit) | Increments (Unit/Exchange) |
|---|---|---|---|---|
| MiniMed 530G (551/751) Revel (523/723) | 1-200 grams/unit or 0.075-15 units/exchange | 15 grams/unit or 1 unit/exchange | 0.1 g/u (for ratios up to 10 g/u) ; 1.0 g/u (for ratios greater than 10 g/u) | 0.001 u/exch for 0.075-0.099 u/exch; 0.01 u/exch for 0.10-9.99 u/exch; 0.1 u/exch for 10.0-15.0 u/exch |
| 522/722 515/715 | 3-150 grams/unit or 0.1-5.0 units/exchange | 15 grams/unit or 1 unit/exchange | 1.0 g/u | 0.1 u/exchange |
| 512/712 | 3-75 grams/unit or 0.2-5.0 units/exchange | 15 grams/unit or 1 unit/exchange | 1.0 g/u | 0.1 u/exchange |
ol>
- For MiniMed 530G (551/751), Revel (523/723) Main Menu > Bolus > Bolus Setup > Bolus Wizard Setup > Edit Settings
- For 522/722, 515/715, 512/712 Main Menu > Bolus > Bolus Wizard Setup > Edit Settings
If you use exchanges as your carb units: Carb ratio is the number of insulin units that are needed to cover one (1.0) carb exchange.
Setting the BG Units Device: Revel (523/723), 522/722, 515/715, 512/712 Did You Know: Depending on where you live, blood glucose (BG) is measured in mg/dL (milligrams per deciliter) or mmol/L (millimols per liter). In the United States, mg/dL is the standard.
- Make sure the EDIT SETTINGS screen is open.
- For Revel (523/723) Main Menu > Bolus > Bolus Setup > Bolus Wizard Setup > Edit Settings
- For 522/722, 515/715, 512/712 Main Menu > Bolus > Bolus Wizard Setup > Edit Settings
- Select BG Units, then press ACT,
- The BLOOD GLUCOSE UNITS screen displays. Select mmol/L or mg/dL, then press ACT,
- The EDIT SETTINGS screen shows the BG units you selected.
Setting the Insulin Sensitivity Device: MiniMed 530G (551/751), Revel (523/723), 522/722, 515/715, 512/712 Did You Know: Your insulin sensitivity is the amount that your blood glucose (BG) level is reduced by one unit of insulin. This value is used to calculate a suggested insulin dose to correct a high BG.
| Device | Allowed Range | Default Setting | Increments |
|---|---|---|---|
| MiniMed 530G (551/751) Revel (523/723) | 10-400 mg/dL/u | 50 mg/dL/u | 1 mg/dL/u |
| Revel (523/723) 522/722 515/715 | 10-400 mg/dL/u (0.5-22.2 mmol/L/u) | 50 mg/dL/u (2.8 mmol/L/u) | 1 mg/dL/u or 0.1 mmol/L/u |
| 512/712 | 10-250 mg/dL (0.5-13.9 mmol/L) | 50 mg/dL/u (2.8 mmol/L/u) | 1 mg/dL or 0.1 mmol/L/u |
ol>
- For MiniMed 530G (551/751), Revel (523/723) Main Menu > Bolus > Bolus Setup > Bolus Wizard Setup > Edit Settings
- For 522/722, 515/715, 512/712 Main Menu > Bolus > Bolus Wizard Setup > Edit Settings
Important: Insulin sensitivity values are normally between 20 mg/dL/u to 100 mg/dL/u (1.1 mmol/L/u to 5.6 mmol/L/u). If your value is outside this range, a warning message will appear on the screen.
- The SET START TIME 2 screen appears. The dashes under the screen name flash. The first insulin sensitivity is now set. If you do not need a second insulin sensitivity, press ESC, If you need to set up another insulin sensitivity, follow steps 6 through 9.
- In the SET START TIME 2 screen enter the time of the day you want this insulin sensitivity to become active.
- Press ACT, The INS SENSITIVITY 2 screen appears.
- The default sensitivity value flashes. Select the value for this insulin sensitivity.
- Press ACT, The SET START TIME 3 screen appears. The second insulin sensitivity is now set.
- If you do not need to set up any more insulin sensitivities, press ESC, If you need to set up more insulin sensitivities, repeat steps 6 through 9 above for each insulin sensitivity.
Setting the BG Targets Device: MiniMed 530G (551/751), Revel (523/723), 522/722, 515/715, 512/712 Did You Know: When you set your BG Target, your blood glucose will be corrected to those high and low target values. The Bolus Wizard feature uses your targets to calculate correction bolus amounts.
| Device | Allowed Range | Default Setting | Increments |
|---|---|---|---|
| MiniMed 530G (551/751) | 60-250 mg/dL | 100-100 mg/dL | 1 mg/dL |
| Revel 523/723 522/722 515/715 | 60-250 mg/dL (3.3-13.9 mmol/L) | 100-100 mg/dL (5.6-5.6 mmol/L) | 1 mg/dL or 0.1 mmol/L |
| 512/712 | 80-160 mg/dL (4.4-8.9 mmol/L) | 100-100 mg/dL (5.6-5.6 mmol/L) | 1 mg/dL or 0.1 mmol/L |
ol>
- For MiniMed 530G (551/751), Revel (523/723) Main Menu > Bolus > Bolus Setup > Bolus Wizard Setup > Edit Settings
- For 522/722, 515/715, 512/712 Main Menu > Bolus > Bolus Wizard Setup > Edit Settings
Setting the Active Insulin Time Device: MiniMed 530G (551/751), Revel (523/723), 522/722, 515/715 Did You Know: Active insulin is the bolus insulin that has already been delivered to your body, but has not yet been used. The pump considers your active insulin setting in determining any active insulin still in your body from your prior boluses.
| Device | Allowed Range | Default Setting | Increments |
|---|---|---|---|
| MiniMed 530G (551/751) Revel (523/723) 522/722 515/715 | 2-8 hours | 6 hours | 1 hour |
ol>
- For MiniMed 530G (551/751), Revel (523/723) Main Menu > Bolus > Bolus Setup > Bolus Wizard Setup > Edit Settings
- For 522/722, 515/715 Main Menu > Bolus > Bolus Wizard Setup > Edit Settings
Review Your Settings Device: MiniMed 530G (551/751), Revel (523/723), 522/722, 515/715, 512/712
- Go to the REVIEW SETTINGS screen.
- For MiniMed 530G (551/751), Revel (523/723) Main Menu > Bolus > Bolus Setup > Bolus Wizard Setup > Review Settings
- For 522/722, 515/715, 512/712 Main Menu > Bolus > Bolus Wizard Setup > Review Settings
- Scroll through the text to view your Bolus Wizard settings.
- Exit the menus when you are done.
9404039-012 20110713
Does Medtronic make insulin?
Technical Specifications –
| Water Resistance | Waterproof pump, protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours. Although it’s designed to be waterproof, drops and bumps that occur over time can make it more vulnerable to damage from water. We recommend removing your pump before swimming or bathing. |
| Environmental Conditions | The MiniMed™780G insulin pump system is designed to withstand most conditions encountered in your daily life. Pump storage temperature range is from -4ºF (-20ºC) to 122ºF (50ºC). Air pressure range is from 700 hPa to 1060 hPa (10.2 psi to 15.4 psi). |
| Attitude Range |
|
| Insulin type | Rapid-acting U100 insulin (Humalog R and NovoRapid R ) that has been prescribed by a healthcare professional. |
| Bolus delivery | Bolus Speeds
Programming Increments
Max bolus 25 units |
| Basal Rate Delivery | 0 to 35 units per hour. |
| Screen |
|
| Battery & Power | The pump requires one new AA (1.5V) battery. For best results, use a new AA lithium (FR6) battery. The pump also accepts an AA alkaline (LR6) or a fully charged AA NiMH (HR6) nickel-metal hydride rechargeable battery. |
| Pump memory | At any time you can review 90 days of pump history. |
| Size | The pump dimensions in centimetres are approximately 5.36 width x 9.68 length x 2.49 depth. The weight of the pump is approximately 106 grams. |
| Warranty | Depends on the insurer and the method of purchase. |
table>
Is Medtronic an insulin pump?
Diabetes – MiniMed™ 670G System Here are some of the benefits people can experience when using the MiniMed™ 670G system. The system automatically changes the amount of background insulin you receive based on your body’s needs. The system allows you to deliver insulin through a small tube that is hidden under your clothing, rather than manual injections. With the push of a button, you can give yourself insulin.
Auto Mode automatically adjusts basal insulin every five minutes based on the patient’s continuous glucose monitoring (CGM) readings, helping to keep sugar levels in the target range for fewer lows and highs — day and night.* †3 Manual Mode with the Suspend before low option proactively addresses lows and rebound highs by automatically suspending insulin before patients reach a pre-selected low glucose limit, resuming delivery when sensor glucose levels recover.2
Waterproof pump, protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours. ¶ The pump dimensions in inches are approximately 2.1 width x 3.78 length x 0.96 depth. The weight of the pump is approximately 3 ounces.
- The MiniMed™ 670G insulin pump system is designed to withstand most conditions encountered in your daily life.
- Pump storage temperature range is from -4 °F (-20 °C) to 122 °F (50 °C).
- Air pressure range is from 700 hPa to 1060 hPa (10.2 psi to 15.4 psi).
- At any time the user can review 90 days of pump history.
Medtronic Diabetes provides a variety of infusion sets to fit your needs. Used with your pump for Continuous Glucose Monitoring (CGM). A device that connects to a glucose sensor. The transmitter collects data measured by the sensor and wirelessly sends this data to monitoring devices.
Standard: 1.5 units/minute Quick: 15 units/minute 0.025 units, 0.05 units, 0.1 units Altitude Range Pump operating range is from 10.2 psiA (70.33 kPa) to 15.4 psiA (106.18 kPa). Storage range is from 7.2 psiA (49.64 kPa) to 15.4 psiA (106.18 kPa). – LED (Light-emitting Diode) – Time out: 15 seconds (default), 30 seconds, one minute, three minutes – Time out when battery is low: 15 seconds (default), 30 seconds 0 to 35 units per hour or the Max Basal Rate amount, whichever is lower.
Used with the pump for CGM. The sensor is a small part of the continuous glucose monitoring system inserted just below the skin to measure glucose levels in the interstitial fluid. Used to upload system data to the diabetes management software using a USB port on your computer.
- The serter is used as an aid for inserting the sensor.
- It is indicated for single-patient use and is not intended for multiple patient use.
- The pump requires one new AA (1.5 V) battery.
- For best results, use a new AA lithium (FR6) battery.
- The pump also accepts an AA alkaline (LR6) or a fully charged AA NiMH (HR6) nickel-metal hydride rechargeable battery.
Medtronic reservoir MMT-332A, 3.0 ml (300-unit). The MiniMed™ 670G system comes with a compatible meter. It wirelessly connects to your pump, allowing you to send BG meter readings to your pump. * Refers to SmartGuard™ Auto Mode feature; The MiniMed™ 670G system can automatically increase or decrease insulin delivery based on continuous glucose monitoring (CGM) values; however, the user must still administer meal boluses.
- ADA recommendation for a glucose range is 80-180 mg/dL in non-pregnant adults with diabetes.
- Based on clinical study data in pivotal trial.
- Individual results may vary.
- Based on sensor glucose.
- Approved for ages 14 and older.
- § Refers to AutoMode.
- Some interaction required.
- Individual results may vary.
|| Arm sensor insertion site, 3-4 calibrations/day. Approved for ages 14-75 years. ¶ At the time of manufacture and when the reservoir and tubing are properly inserted, your pump is waterproof. It is protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours.
- This is classified as IPX8 rating.
- See user guide for more details.
- The sensor and transmitter are water-resistant at 8 feet (2.4 meters) for up to 30 minutes.
- CGM readings may not be transmitted from the CGM to the pump while in water.1 Gopalakrishnan S, Mueckler J, Fogel C.
- The MiniMed™ 670G hybrid closed loop system & patient reported outcomes concerning quality of life measures (n=2.S34).
Poster #963-P presented at the 78th Scientific Sessions of the American Diabetes Association: 2018 June 22 26, Orlando, Florida, USA.2 Bergenstal R, Garg S, Weinzimer S, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes.
JAMA,2016;316(13):1407-1408 3 dQ&A Patient Panel. dQ&A 2017. Important Safety Information: MiniMed™ 670G System The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin.
The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.
The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR ® NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy.
You’re a #MedtronicChampion!
All therapy adjustments should be based on measurements obtained using the CONTOUR ® NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR ® NEXT LINK 2.4 blood glucose meter.
- Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test.
- It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements.
Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms.
Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult and the appropriate user guide at The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care. : Diabetes – MiniMed™ 670G System
Is there a cure coming soon for diabetes?
What lifestyle changes can help me manage my diabetes? – Even though there’s no diabetes cure, diabetes can be treated and controlled, and some people may go into remission. To manage diabetes effectively, you need to do the following: Manage your blood sugar levels,
- Now what to do to help keep them as near to normal as possible every day: Check your glucose levels frequently.
- Take your diabetes medicine regularly.
- And balance your food intake with medication, exercise, stress management, and good sleep habits.
- Plan what you eat at each meal.
- Stick to your diabetes eating plan as often as possible.
Bring healthy snacks with you. You’ll be less likely to snack on empty calories. Exercise regularly. Exercise helps you keep you fit, burns calories, and helps normalize your blood glucose levels. Keep up with your medical appointments. That includes your doctor, diabetes educator, ophthalmologist, dentist, podiatrist, and other health care professionals.
- Weight Loss Surgery After weight loss surgery, many people with type 2 diabetes see their blood sugar levels return to near normal.
- Some experts call this a remission.
- It’s not unusual for people to no longer need diabetes medicines after weight loss surgery,
- The more weight a person loses after surgery, the greater improvement in blood sugar control.
After surgery, if extra weight returns, your diabetes can return too. Reaching and keeping a healthy weight are very important for managing diabetes. You should also follow your recommended diabetes diet, exercise regularly, manage your stress, and see your doctor regularly for necessary checkups.
How much does artificial pancreas cost?
Costs – An artificial pancreas cost will vary from individual to individual, as it depends on the type of insurance one has. However, there have been estimates made for what it would cost to get one of these closed-loop insulin pumps. For an artificial pancreas from Medtronic, you may expect to pay somewhere in the range of 5,000-8,000 dollars.
The price may go up from there depending on how many glucose sensors the individual goes through in a year. Keep in mind that with these systems, insulin is still needed. The system does not come with insulin. Needless to say, proper management of diabetes is pricey and burdensome. This is why Prescription Hope exists.
Get your insulin for a set, affordable costs every month.
Can the pancreas rebuild itself?
The exocrine pancreas is composed of acinar cells that synthesize and secrete digestive enzymes, ductal cells that funnel the enzymes into the small intestine, and central acinar cells. The exocrine pancreas can regenerate spontaneously and robustly in both animals and humans.
How much does 1 unit of insulin lower blood sugar?
Your Insulin Therapy Your doctor has given you insulin to help control your diabetes. You need two kinds of insulin: basal and mealtime insulin. Sometimes insulin is premixed for you. Keep a record of your blood sugar and insulin shots every day so the amounts of insulin can be changed to fit your lifestyle. Your basal insulin type and dose are (your doctor will fill in the blanks) :
NPH insulin: Inject _ units at _ a.m. and _ units at _ p.m. Ultralente or glargine (Lantus): inject _ units at _ a.m./p.m. Basal insulin provides steady levels of insulin. NPH lasts 10 to 16 hours. Ultralente and glargine last 24 hours. Take your basal insulin at the same time every day. Do not skip your basal insulin shots, even if you are sick. Your body still needs the basal insulin. Do not mix glargine with other insulins. NPH can be mixed. Do not take glargine if you are pregnant or planning to become pregnant. Your basal insulin dose should be increased every seven days until your fasting blood sugar level is between 90 and 130 mg per dL. Talk to your doctor about how much to increase your dose.
Low blood sugar (this is called hypoglycemia) can happen if you take too much insulin,
Symptoms of low blood sugar include shakiness, weakness, dizziness, confusion, and headache. Some people may not have symptoms. Check your blood sugar level if you have any of these symptoms. You also should check your blood sugar level during your insulin’s peak of activity (talk to your doctor about this). If your blood sugar level is below 70 mg per dL, follow the Rule of 15 : Eat or drink 15 grams of carbohydrates (e.g., one half glass of orange juice or one slice of bread). Wait 15 minutes, and test your blood sugar level again. If your blood sugar level is still below 70 mg per dL, do steps 1 and 2 again. If your blood sugar level now is above 70 mg per dL, go back to your usual testing schedule. Your risk of low blood sugar depends on the kind of insulin you use and how long it works. Aspart and lispro last 4 hours, regular insulin lasts 6 hours, NPH lasts 10 to 16 hours, and glargine and ultralente last 24 hours. If you have trouble getting your blood sugar level back above 70 mg per dL, call your doctor or local emergency room for help.
Your mealtime insulin type and dose are (your doctor will fill in the blanks) :
Regular insulin: Inject it 30 to 60 minutes before you eat. Lispro (Humalog) or aspart (NovoLog): Inject it 5 to 15 minutes before you eat.
How much insulin you use before meals changes from meal to meal. Spell the word “SAFE” to figure out how much insulin you will need at mealtime: S upplemental insulin—supplemental, or corrective, insulin will get your blood sugar level back into the range of 90 to 130 mg per dL before meals.
Test your blood sugar level before the meal (if your blood sugar level is below 70 mg per dL between meals, follow the Rule of 15). Use the table below to find how much you need to change your insulin dose. One unit of insulin should cause your blood sugar level to drop 30 to 50 mg per dL, but you may need more insulin to get the same effect.
A ctivity—take _ units less insulin if you plan to exercise after the meal. F ood—carbohydrates; take 1 unit of insulin for every 10 grams of carbohydrate in your meal. A typical meal has 45 to 60 grams of carbohydrates, so you will need to take about 4 to 6 units of insulin per meal.
- People with insulin resistance may need to take more insulin to get the same effect.
- E xperience—You will learn how much insulin you need at different times.
- Eep a record of your blood sugar levels and the amount of insulin you take every time.
- This will help you remember what has worked for you in the past.
Bring this record with you every time you see your doctor. SAFE total: _ This is the amount of mealtime insulin you should inject. : Your Insulin Therapy
What is a good insulin sensitivity score?
Individuals with elevated fasting insulin and/or C-peptide levels may have IR,11 which is reflected in the insulin resistance score. An insulin resistance score of suggests that an individual has normal insulin sensitivity.
What should my insulin resistance level be?
How Do I Get My Insulin Tested? – As we mentioned above, insulin testing is not typically included as part of routine care. Fortunately, tests are still fairly easy for most people to obtain. You can either request one from your primary care doctor or work directly with a commercial laboratory.
- The most common test—a fasting insulin test—requires a basic blood draw and may cost as little as $20.
- As the name suggests, you’ll need to abstain from food for eight hours before your blood sample is taken.
- The test results will probably be available in a day or two and will most likely be listed in microunits per milliliter (sometimes written as μU/mL, μIU/mL, or mU/mL).
There is also a slightly more complex test available that paints a clearer picture of your metabolic health. It’s called HOMA-IR—the Homeostatic Model Assessment of Insulin Resistance. This test measures not just your fasting insulin but your fasting glucose.
- By analyzing these two numbers together, we can see how hard your body is working to control your blood sugar.
- Your HOMA-IR test score will be a single number.
- A score of 1 or less is generally interpreted as the healthy, insulin-sensitive range (though it could also mean low glucose or insulin levels), while a higher score may signify insulin resistance—but how high, exactly, is unclear.
Some research groups have put the safe HOMA-IR ceiling at 1.775 in non-diabetic people; others have set it at 1.83 ; still others have designated a score of 2.5 as the insulin resistance threshold, Note that the original mathematical formula used for HOMA-IR has been largely replaced by a more sophisticated model called HOMA2, so you may see this term in your test results.
- Finally, there is a way to infer your insulin sensitivity from a standard cholesterol test.
- When a doctor tests your lipid profile, the results typically include HDL, LDL, and triglycerides.
- For a directional approximation of your insulin sensitivity, just divide triglycerides by HDL.
- If you score above a certain cutoff, this may suggest insulin resistance; researchers have argued that this threshold varies by ethnicity.
One group has proposed a ceiling of 2 for non-Hispanic Black people, 2.5 for African American men, and 3 for non-Hispanic White and Mexican-American people. Note that this approach has limitations. Some research has set the insulin resistance cutoff higher, at 3.5, for this method.
Why is Medtronic so successful?
Fundamentals – Revenues of Medtronic have almost doubled over the last decade, as sales are up 87.5%. The revenue growth is the result of organic growth and the rollout of new products, as well as acquisitions. The most significant acquisition over the last decade was the Covidien acquisition. 
Data by YCharts The EPS (earnings per share) is misleading in this graph. Over the last decade, the EPS has decreased by 4.5%. These figures are GAAP figures, and they include one-time non-cash expenses that are distorting the growth. Using non-GAAP figures, it can be seen that Medtronic has grown its EPS by 48% over the last decade. 
Data by YCharts The dividend is one of Medtronic’s brightest points. The company has been paying and increasing its dividend annually for 44 years. The dividend is likely safe as the payout ratio is 81% using GAAP earnings and 50% using non-GAAP earnings. 
Data by YCharts In addition to dividends, companies tend to return capital to shareholders via share repurchase plans. Buybacks supplement the EPS growth as they lower the number of outstanding shares. Therefore, they are most efficient when the share price is low. 
Data by YCharts
What is the newest insulin?
A fast-acting mealtime insulin 00:04-00:07 Narrator: If you administer insulin at mealtime for your diabetes.00:10-00:12 Narrator:,things may not always go according to plan.00:15-00:21 Narrator: Lyumjev is a fast-acting insulin used to treat adults with type 1 and type 2 diabetes for the control of high blood sugar.
- 00:21-00:29
- Narrator: As a fast-acting insulin, Lyumjev helps control high blood sugar levels after you eat, similar to how natural insulin works after meals in people without diabetes.
- Caption: Helps control natural after-meal blood sugar spikes * * Lyumjev is a mealtime insulin.
- Descriptive Clue: The caption has blue and white text and is accompanied by a red blood drop icon
- 00:29-00:31
- Narrator: Lyumjev is proven to reduce A1C.
- Caption: Proven A1C reduction
- Descriptive Clue: The caption has blue and white text and is accompanied by a red arrow icon
- 00:32-00:38
Narrator: Do not take Lyumjev if your blood sugar is too low or if you are allergic to any of its ingredients. Do not reuse needles or share insulin supplies. Caption: Sharing insulin supplies may lead to infection.00:39-00:44 Narrator: Rotate your injection site with each dose. Do not change the type of insulin you take, or your dose, without talking to your doctor.
- Caption: Do not inject into the exact same spot.
- 00:44-00:46
- Narrator: Check your blood sugar levels while taking Lyumjev.
- Caption: It’s important to check your blood sugar levels.
00:46-00:58 Narrator: The most common side effect is low blood sugar, which may be life-threatening. Symptoms may include dizziness or lightheadedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, hunger, anxiety, irritability, and mood changes.
- Caption: The most common side effect is low blood sugar.00:59-01:04 Narrator: Severe, life-threatening allergic reactions may occur.
- Get medical help right away if you have symptoms of allergic reaction.
- Caption: Get medical help right away if you have a severe allergic reaction.
- Symptoms can include a rash over your whole body, trouble breathing, a fast heartbeat, swelling of your face, tongue, or throat, sweating, or feeling faint.01:04-01:12 Narrator: Taking thiazolidinediones (TZDs) with Lyumjev may cause serious side effects like heart failure that can lead to death even if you have never had heart failure before.
Caption: Taking TZDs (thiazolidinediones) with Lyumjev may cause heart failure, even if you’ve never had heart problems before. If you have heart failure, it may get worse.
- 01:12-01:16
- Narrator: High blood sugar and high ketone levels in your blood or urine may occur suddenly when using Lyumjev in a pump.
- 01:17-01:25
- Narrator: Other possible side effects include low potassium in your blood; reactions, pain, skin thickening, or pits at the injection or infusion site; itching; rash; and weight gain.
- 01:25-01:28
- Narrator: Make your smaller highs feel like big wins.
- 01:28-01:30
- Narrator: Ask your doctor if Lyumjev is right for you.
- Caption: Lyumjev 100 units/ml insulin lispro-aabc injection
For more information about Lyumjev, call 1-800-LillyRx (1-800-545-5979) or visit www.Lyumjev.com and talk to your doctor. Lyumjev ® and KwikPen ® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates, and they are available by prescription only. PP-UR-US-0557 08/2021 © Lilly USA, LLC 2021, All rights reserved. : A fast-acting mealtime insulin
Which company sells the most insulin?
Scaling up and diversifying the global insulin market – The report finds that the main insulin manufacturers are pursuing a patchwork of strategies to expand access to their products in LMICs, including paediatric programmmes, price ceilings, and equitable pricing policies.
Eli Lilly, Novo Nordisk and Sanofi have diverse strategies in place to expand access to their products. Notably, Novo Nordisk and Sanofi have recently taken steps to apply integrated business approaches encompassing some of their insulin products. However, there are persistent gaps in access to all insulins; most affordability strategies remain primarily focused on human insulins and few are found for analogue products.
It is within these companies’ abilities to expand access if they build on the strategies they have already employed, with the report identifying ways in which they are now seeking sustainable approaches to scaling up access. Such approaches will need to be holistic and consider insulin within the broader contest of diabetes care, including patients’ access to all the products needed, including monitoring devices (glucometers and test strips) and delivery devices (syringes and injection pens).
What insulin does Medtronic pump use?
Available 24/7 –
Giving you and your patients the ability to view data whenever needed.
Your patients can now use their smartphones to view their data. This means they can easily and discreetly track their glucose levels and get notified of highs and lows. Available for care partners, this app helps keep everyone in the loop. Up to five care partners can now follow a pump user and receive high and low notifications.
| Specifications | |
|---|---|
| Water Resistance | At the time of manufacture and when the reservoir and tubing are properly inserted, your pump is waterproof. It is protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours. This is classified as IPX8 rating. See user guide for more details. The sensor and transmitter are water-resistant at 8 feet (2.4 meters) for up to 30 minutes. CGM readings may not be transmitted from the CGM to the pump while in water. |
| Environmental Conditions | The MiniMed™ 770G insulin pump system is designed to withstand most conditions encountered in your daily life. Pump storage temperature range is from -4°F (-20°C) to 122°F (50°C). Air pressure range is from 700 hPa to 1060 hPa (10.2 psi to 15.4 psi). |
| Altitude Range |
|
| Insulin Type | Rapid-acting U100 insulin (Humalog ® and NovoLog ® ) that has been prescribed by a healthcare professional. |
| Bolus Delivery | Bolus Speed
Programming Increments
|
| Basal Rate Delivery | 0 to 35 units per hour or the Max Basal Rate amount, whichever is lower. |
| Screen |
|
| Battery & Power | The pump requires one new AA (1.5 V) battery. For best results, use a new AA lithium (FR6) battery. The pump also accepts an AA alkaline (LR6) or a fully charged AA NiMH (HR6) nickel-metal hydride rechargeable battery. |
| Pump Memory | At any time you can review 90 days of pump history. |
| Size | The pump dimensions in inches are approximately 2.1 width x 3.78 length x 0.96 depth. The weight of the pump is approximately 3 ounces. |
| Warranty |
|
table>
Complete the form below and a representative will follow up with additional information. * Refers to SmartGuard™ Auto Mode. Some user interaction required. Induvial results may vary. † Based on real world evidence comparing 54,009 MiniMed™ 670G users vs.59,333 MiniMed™ 770G users.
- This program allows MiniMed™ 770G system users a software upgrade at no charge within one year from the date of this software approval. Software approval will be announced.
- Software upgrade process is subject to change. The process may result in healthcare provider office visit and may result in out-of-pocket expenses such as co-pay, depending on insurance coverage. The process may require the completion of product related training.
- This program includes the insulin pump software only. CGM products and consumables are not included in this offer.
- Warranty dates do not reset. The replacement warranty date of an insulin pump upgraded with the software will remain the same as the replacement warranty date of the initial pump purchased. Your warranty date does not impact eligibility for a software update.
- MiniMed™ pumps and software have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your healthcare provider regarding your eligibility to receive the software upgrade based on the labeling of the upgrade, which may differ from the labeling of the MiniMed™ 770G pump.
- Insurance coverage and plan design varies and may impact the ability to upgrade. Coverage is contingent upon your health insurance medical policy guidelines. Restrictions and medical necessity requirements may apply.
- A valid prescription will be required for this software upgrade. All participants should consult their healthcare provider for all therapy related decisions.
- Program terms and conditions are subject to change at any time and without notice. Other restrictions may apply.
Important Safety Information: MiniMed TM 770G System with SmartGuard TM Technology The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin.
The MiniMed™ 770G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose (SG) values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 770G system consists of the following devices: MiniMed™ 770G insulin pump, the Guardian™ Link (3) transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the Accu-Chek® Guide test strips.
- The system requires a prescription.
- The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required.
- All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter.
Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. WARNING: Do not use the SmartGuard™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day.
A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard™ Auto Mode. WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women.
For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult and the appropriate user guide at The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc.
How does Medtronic insulin pump work?
The MiniMed ™ 770G insulin pump system automatically adjusts background insulin every 5 minutes. Using real-time glucose readings, the system is able to calculate a personalized amount of insulin to deliver based on your needs.
Who should not use an insulin pump?
You should not use insulin pumps if you are not willing to test your blood sugar levels often. Using an insulin pump gives you more freedom with your diet and activity level, but you must check your blood sugar levels often to make sure they are near your target range.
- You have to be willing to be connected via catheter to the device most of the time.
- If you have vision problems that prevent you from seeing the buttons and screen on the device or hearing problems that prevent you from getting auditory alerts and alarms, you should consider carefully whether this is a device you will be able to work with.
A pump with an automatic glucose monitor is available for type 1 diabetes patients 14 and older, but it still requires maintenance and the ability to respond to notifications. For example, if a catheter comes out and you are not aware that you are not getting insulin, you could get diabetic ketoacidosis.
- Insulin pumps may not be suitable for people with liver or kidney disease, certain allergies and women who are breastfeeding or pregnant.
- You should discuss these conditions with your doctor to determine if it is safe for you to use an insulin pump.
- Insulin pumps can be pricey, too, and perhaps not preferable to those without adequate resources or insurance coverage.
Some patients have gained weight as a result of using insulin pumps, too. Moreover, you should not attempt to use an insulin pump until a healthcare professional has fully explained how it works to you.
What does the Medtronic monitor do?
Remote Monitoring for Implanted Heart Devices If you have an implanted heart device, ongoing care doesn’t end at the implant. It’s important to maintain a connection with your doctor or clinic for the life of your device. One of the best ways to do this is through remote monitoring. Remote monitoring is a way for your implanted heart device to communicate with your doctor or clinic, potentially reducing the number of times you have to travel to your clinic for an implanted heart device check.
Detects abnormal heart rhythms and issues with heart devices faster.1,2 Reduces hospitalizations and ER visits.3,4 Increases quality of life.4 Provides a sense of security and peace of mind.5-7
Remote monitoring is prescribed by your doctor. It provides easy access to information that allows your doctor to:
Manage your heart condition. Monitor your implanted heart device. Obtain information from your implanted heart device on an as-needed basis.
Bluetooth®-enabled Medtronic heart devices can communicate directly to your clinic via the MyCareLink Heart mobile app, available for Apple® and Android™ mobile devices. The MyCareLink Relay home communicator sends data from your heart device directly to your clinic using Wi-Fi or cellular data. Medtronic offers hardware and app-based monitors designed to fit your lifestyle. Your doctor or clinic will help you determine the right monitoring option for you.
- MyCareLink Heart Mobile App* The MyCareLink Heart mobile app allows you to use a smartphone or tablet as a monitor.
- Whether at home or on the go, you’ll stay connected to your clinic using cellular data or Wi-Fi.
- The app also gives you access to information about your heart device, including implant date, heart device type, model, and serial number, and it will send you notifications on transmission and connectivity status.
This option may be best if you:
Own a compatible smartphone or tablet Keep a smartphone or tablet nearby at least three hours per day
*Keep your mobile device and software current so you can continue to use the app. MyCareLink Relay Home Communicator The MyCareLink Relay home communicator sends data from your heart device directly to your clinic using Wi-Fi or cellular data. This option may be best if you rarely carry your mobile device — like a smartphone or tablet — with you. MyCareLink Smart Monitor* The MyCareLink Smart monitor uses a handheld reader and an app to send heart device data to your clinic through your mobile device. This option may be best if you:
Have a Medtronic pacemaker, including CRT-P Own a mobile device like a smartphone or tablet or have a caretaker who owns a smartphone or tablet
*Keep your mobile device and software current so you can continue to use the app.
The MyCareLink monitor sends data from your heart device directly to your clinic using a cellular network. This option may be best if you do not have a compatible smart device.The MyCareLink monitor is the only option for patients with older ICD/CRT-D devices.
U.S. mail: Medtronic Heart Rhythm Patient Services Mail Stop MVS 14 8200 Coral Sea St. NE Mounds View, MN 55112 MyCareLink Connect website: for Medtronic implanted heart devices The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc.
and any use of such marks by Medtronic is under license. Apple, iPhone, iPad, and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android™ and Google Play™ store are trademarks of Google LLC.1 Crossley GH, Boyle A, Vitense H, Chang Y, Mead RH; CONNECT Investigators.
The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol, March 8, 2011;57(10):1181-1189.2 Chen J, Wilkoff BL, Choucair W, et al.
Design of the Pacemaker Remote Follow-up Evaluation and Review (PREFER) trial to assess the clinical value of the remote pacemaker interrogation in the management of pacemaker patients. Trials, April 3, 2008;9:18.3 Small R, Tang W, Wickemeyer W, et al. Managing Heart Failure Patients with Intra-Thoracic Impedance Monitoring: A Multi-Center US Evaluation (OFISSER).
J Card Fail, August 2007;13(6 Supp 2):S113-S114.4 Landolina M, Perego GB, Lunati M, et al. Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: the evolution of management strategies of heart failure patients with implantable defibrillators (EVOLVO ) study.
- Circulation,
- June 19, 2012;125(24):2985-2992.5 Marzegalli M, Lunati M, Landolina M.
- Remote monitoring of CRT-ICD: The Multicenter Italian CareLink Evaluation — Ease of Use, Acceptance, and Organizational Implications.
- Pacing Clin Electrophysiol,
- October 2008;31(10):1259-1264.6 Petersen HH, Larsen MC, Nielsen OW, Kensing F, Svendsen JH.
Patient satisfaction and suggestions for improvement of remote ICD monitoring. J Interv Card Electrophysiol, September 2012;34(3):317-324.7 Ricci RP, Vicentini A, D’Onofrio A, et al. Impact of in-clinic follow-up visits in patients with implantable cardioverter defibrillators: demographic and socioeconomic analysis of the TARIFF study population.
Is Medtronic a healthcare provider?
Medtronic offers the broadest range of innovative healthcare technology for the treatment of cardiac and vascular diseases and arrhythmias, helping solve even the most complicated challenges.